Considering that SARS-CoV-2 possesses countermeasures to block IFN activity,6 and that STING can function via IFN-independent mechanisms such as translation inhibition59 and autophagy,60 we reason that STING agonist-based therapies may offer new opportunities to treat COVID-19. The gene discussed is IFNA1; the disease is COVID-19.